MRS-1706
MRS-1706 je selektivni inverzni agonist adenozinskog A2B receptora.[1] On inhibira otpuštanje interleukina i ima antiinflamatorno dejstvo.[2][3]
Nazivi | |
---|---|
IUPAC naziv
N-(4-Acetilfenil)-2-[4-(2,3,6,7-tetrahidro-2,6-diokso-1,3-dipropil-1H-purin-8-il)fenoksi]acetamid
| |
Drugi nazivi
MRS 1706
| |
Identifikacija | |
3D model (Jmol)
|
|
| |
Svojstva | |
C27H29N5O5 | |
Molarna masa | 503,56 |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
verifikuj (šta je ?) | |
Reference infokutije | |
Reference
уреди- ^ Li Q, Ye K, Blad CC, den Dulk H, Brouwer J, Ijzerman AP, Beukers MW. ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor. Journal of Pharmacology and Experimental Therapeutics. 2007 Feb;320(2):637-45. PMID 17077318
- ^ Vazquez JF, Clement HW, Sommer O, Schulz E, van Calker D. Local stimulation of the adenosine A2B receptors induces an increased release of IL-6 in mouse striatum: an in vivo microdialysis study. Journal of Neurochemistry. 2008 May;105(3):904-9. PMID 18088370
- ^ Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Dikov MM, Blackburn MR, Biaggioni I, Feoktistov I. Effect of A2B adenosine receptor gene ablation on proinflammatory adenosine signaling in mast cells. Journal of Immunology. 2008 Jun 1;180(11):7212-20. PMID 18490720